###begin article-title 0
Variance of the SGK1 Gene Is Associated with Insulin Secretion in Different European Populations: Results from the TUEF, EUGENE2, and METSIM Studies
###end article-title 0
###begin p 1
Conceived and designed the experiments: ML GS US TH OP FM NS AF HUH. Performed the experiments: AS JW JK ES OP SAS. Analyzed the data: BF PW AS JW JK ML GS ES US TH OP FM FL TR SU NS AF HUH. Contributed reagents/materials/analysis tools: FM HUH. Wrote the paper: BF PW AF.
###end p 1
###begin title 2
Hypothesis
###end title 2
###begin p 3
###xml 189 195 <span type="species:ncbi:9606">humans</span>
Serum- and Glucocorticoid-inducible Kinase 1 (SGK1) is involved in the regulation of insulin secretion and may represent a candidate gene for the development of type 2 diabetes mellitus in humans.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
Three independent European populations were analyzed for the association of SGK1 gene (SGK) variations and insulin secretion traits. The German TUEF project provided the screening population (N = 725), and four tagging SNPs (rs1763527, rs1743966, rs1057293, rs9402571) were investigated. EUGENE2 (N = 827) served as a replication cohort for the detected associations. Finally, the detected associations were validated in the METSIM study, providing 3798 non-diabetic and 659 diabetic (type 2) individuals.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 151 160 151 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C-Peptide</sub>
###xml 164 167 164 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 653 656 651 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ins</sub>
###xml 660 663 658 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 665 667 663 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</italic>
###xml 678 680 674 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XG</italic>
###xml 691 692 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 517 529 <span type="species:ncbi:9606">participants</span>
Carriers of the minor G allele in rs9402571 had significantly higher C-peptide levels in the 2 h OGTT (+10.8%, p = 0.04; dominant model) and higher AUCC-Peptide/AUCGlc ratios (+7.5%, p = 0.04) compared to homozygous wild type TT carriers in the screening population. As interaction analysis for BMIxrs9402571 was significant (p = 0.04) for the endpoint insulin secretion, we stratified the TUEF cohort for BMI, using a cut off point of BMI = 25. The effect on insulin secretion only remained significant in lean TUEF participants (BMI</=25). This finding was replicated in lean EUGENE2 rs9402571 minor allele carriers, who had a significantly higher AUCIns/AUCGlc (TT: 226+/-7, XG: 246+/-9; p = 0.019). Accordingly, the METSIM trial revealed a lower prevalence of type 2 diabetes (OR: 0.85; 95%CI: 0.71-1.01; p = 0.065, dominant model) in rs9402571 minor allele carriers.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 14 17 14 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 245 248 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 105 117 <span type="species:ncbi:9606">participants</span>
The rs9402571 SGK genotype associates with increased insulin secretion in lean non-diabetic TUEF/EUGENE2 participants and with lower diabetes prevalence in METSIM. Our study in three independent European populations supports the conclusion that SGK variability affects diabetes risk.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 163 166 163 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Weyer1">[1]</xref>
###xml 416 419 416 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Shu1">[2]</xref>
###xml 421 424 421 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Schafer1">[3]</xref>
###xml 426 429 426 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Wang1">[4]</xref>
###xml 438 441 438 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Palmer1">[5]</xref>
###xml 443 446 443 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Pascoe1">[6]</xref>
###xml 448 451 448 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Steinthorsdottir1">[7]</xref>
###xml 453 456 453 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Stancakova1">[8]</xref>
###xml 466 469 466 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Palmer1">[5]</xref>
###xml 471 474 471 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Staiger1">[9]</xref>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Boesgaard1">[10]</xref>
###xml 490 493 490 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Palmer1">[5]</xref>
###xml 504 507 504 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Pascoe1">[6]</xref>
###xml 509 512 509 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Staiger1">[9]</xref>
###xml 514 518 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Grarup1">[11]</xref>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Staiger2">[12]</xref>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Grarup2">[13]</xref>
Type 2 diabetes arises when insulin resistance cannot be compensated for with increased insulin secretion owing to a gradual loss of pancreatic beta-cell function [1]. Recently, genome-wide association studies have been undertaken to further investigate the genetic background of type 2 diabetes, revealing that many high risk alleles are located within genes that are linked to beta cell function, including TCF7L2 [2], [3], [4], CDKAL1 [5], [6], [7], [8], SLC30A8 [5], [9], [10], IGF2BP2 [5], HHEX/IDE [6], [9], [11], [12], and CDKN2A/B [13]. Our study therefore focuses on genes that play a role in insulin secretion, using a classical candidate-gene approach.
###end p 11
###begin p 12
###xml 226 229 226 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Webster1">[14]</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Chen1">[15]</xref>
###xml 427 431 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Lang1">[16]</xref>
###xml 528 531 527 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 634 638 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Boini1">[17]</xref>
###xml 699 703 698 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Dieter1">[18]</xref>
###xml 705 709 704 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Grahammer1">[19]</xref>
###xml 711 715 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Palmada1">[20]</xref>
###xml 717 721 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Jeyaraj1">[21]</xref>
###xml 745 749 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Lang1">[16]</xref>
###xml 812 815 811 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 934 935 933 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 970 972 969 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 1009 1013 1008 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Ullrich1">[22]</xref>
###xml 1102 1103 1101 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1105 1106 1104 1105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1152 1156 1151 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Ullrich2">[23]</xref>
###xml 191 197 <span type="species:ncbi:9606">humans</span>
###xml 541 545 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
One interesting candidate for the regulation of insulin secretory function is the serum and glucocorticoid inducible kinase SGK1, which is a ubiquitously expressed serine-threonine kinase in humans that is encoded by the gene SGK on chromosome 6q23. SGK1 was originally identified in rodents as a serum and glucocorticoid regulated kinase [14], and was shown to be up-regulated by mineralocorticoids [15], TGF-ss1, and insulin [16]. SGK1 seems to provide an important molecular link between salt and glucose homeostasis, as SGK1-/- knockout mice fed with high-salted chow demonstrated decreased SGK1-dependent cellular glucose uptake [17]. Beyond SGK1 functions in transmembranous glucose transport [18], [19], [20], [21] and insulin signalling [16], SGK1 also plays a role in insulin secretion. In INS-1 cells, SGK gene transcription and protein expression is strongly regulated, and SGK1 up-regulates the activity of voltage-gated K+ channels, which in turn reduces Ca++ influx and inhibits insulin release [22]. Another SGK1-dependent molecular mechanism in insulin secretion is the activation of Na+/K+-ATPase during plasma membrane repolarisation [23].
###end p 12
###begin p 13
###xml 218 221 218 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 319 322 319 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Busjahn1">[24]</xref>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-vonWowern1">[25]</xref>
###xml 483 486 483 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 901 904 901 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 1087 1090 1087 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 242 247 <span type="species:ncbi:9606">human</span>
Taken together, compelling evidence points to a role of this ubiquitously expressed serine/threonine kinase SGK1 in glucose metabolism, especially in the regulation of insulin secretion. So far, studies on the role of SGK genetic variance in human physiology are rather limited. Two studies confirmed an association of SGK variability with blood pressure in a German twin population [24] and the cohort of the Scandinavian Malmo Diet and Cancer Study [25]. We conducted our study on SGK genetic variance and potential associations with insulin secretory function in the German TUEF cohort and the EUGENE2 consortium (Denmark, Finland, Germany, Italy, and Sweden), as these two European diabetes risk populations were extensively phenotyped for insulin secretion traits at the prediabetic stage. To confirm the relevance of associations found for later onset of type 2 diabetes mellitus, corresponding SGK risk alleles were further investigated in the METSIM Trial, which provides a large population-based Finnish cohort for the endpoint diabetes. Analyzing four selected tagging SNPs of SGK, the SNP rs9402571 was consistently found to be associated with altered insulin secretion in both prediabetic populations, and was further confirmed to associate with the prevalence of type 2 diabetes mellitus in the population-based cohort.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 15
###begin p 16
###xml 53 56 53 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 378 381 378 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 530 537 530 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003506-t001">Table 1</xref>
Three independent European cohorts were analyzed for SGK genetic variance and insulin secretion traits for this study. The TUEF project provided the screening population, while EUGENE2 served as a replication cohort for insulin secretion traits. METSIM is a population-based cohort providing both non-diabetic and type 2 diabetic individuals, and was employed for estimation of SGK diabetes-risk alleles. Further details on each of the three study cohorts are provided in the following, with baseline characteristics presented in Table 1.
###end p 16
###begin title 17
Characteristics of the 3 investigated study populations.
###end title 17
###begin p 18
Data are presented as means+/-SD.
###end p 18
###begin p 19
Tuebingen Family Study (South Germany; non-diabetic individuals).
###end p 19
###begin p 20
###xml 70 74 70 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Laakso1">[27]</xref>
###xml 145 148 145 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ins</sub>
###xml 152 156 152 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gluc</sub>
###xml 102 114 <span type="species:ncbi:9606">participants</span>
Finns, Danish, Dutch, Swedish and Germans from the EUGENE2 consortium [27]. Only non-diabetic EUGENE2 participants with complete datasets for AUCIns/AUCGluc calculations were analyzed.
###end p 20
###begin p 21
###xml 22 25 <span type="species:ncbi:9606">Men</span>
METabolic Syndrome In Men (METSIM) cohort from Kuopio (Finland), population-based (non-diabetic and diabetic individuals).
###end p 21
###begin title 22
TUEF cohort
###end title 22
###begin p 23
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Thamer1">[26]</xref>
###xml 721 724 721 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 755 757 755 757 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CP</sub>
###xml 761 764 761 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 1098 1100 1098 1100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CP</sub>
###xml 1104 1107 1104 1107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 521 533 <span type="species:ncbi:9606">participants</span>
###xml 689 701 <span type="species:ncbi:9606">participants</span>
The TUEF (Tuebingen Familiy Study) cohort includes non-diabetic individuals from southern Germany with increased risks for developing type 2 diabetes (family history of type 2 diabetes, diagnosis of impaired fasting glucose). The study protocol included standard procedures as medical history, physical examination, routine blood tests and oral glucose tolerance test with blood sampling (plasma insulin, plasma glucose, plasma C-peptide) at 0, 30, 60, 90 and 120 min [26]. Informed written consent was obtained from all participants, and all study procedures were approved by the local medical ethic research committee of the Faculty of Medicine at the University of Tuebingen. 1000 TUEF participants were genotyped for SGK and phenotyped by OGTT and AUCCP/AUCGlc (see below). For further investigation, individuals with one of the following criteria were excluded: taking medications known to affect glucose tolerance, severe diseases (malignancies, cardiovascular or psychiatric disease, etc.), newly diagnosed diabetes, positive GAD antibodies, and one or more missing parameters needed for AUCCP/AUCGlc calculation. This method of elimination resulted in a final study cohort of 725 non-diabetic individuals.
###end p 23
###begin title 24
EUGENE2 consortium
###end title 24
###begin p 25
###xml 911 915 911 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Laakso1">[27]</xref>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 529 541 <span type="species:ncbi:9606">participants</span>
###xml 743 755 <span type="species:ncbi:9606">participants</span>
Five different European clinical diabetes centres contributed non-diabetic offspring of patients with type 2 diabetes to the EUGENE2 (European network on Functional Genomics of Type 2 Diabetes) consortium, including the Lundberg Laboratory for Diabetes Research (Goteborg, Sweden), the Polyclinic Mater Domini of the University Magna Graecia (Catanzaro, Italy), the Steno Diabetes Center (Copenhagen, Denmark), the Kuopio University Hospital (Kuopio, Finland), and the Tubingen University Hospital (Tubingen, Germany). All study participants underwent a standard medical history, routine laboratory testing, assessment of social issues (alcohol consumption, activity, smoking status), and an OGTT. Informed written consent was obtained of all participants, and the local ethics committees approved the study protocol at the different centres. Further details about the EUGENE2 consortium are provided elsewhere [27].
###end p 25
###begin title 26
METSIM cohort
###end title 26
###begin p 27
###xml 170 173 170 173 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MET</underline>
###xml 180 181 180 181 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</underline>
###xml 189 190 189 190 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</underline>
###xml 192 193 192 193 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</underline>
###xml 424 427 424 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Wang1">[4]</xref>
###xml 612 616 612 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Alberti1">[28]</xref>
###xml 39 51 <span type="species:ncbi:9606">participants</span>
###xml 192 195 <span type="species:ncbi:9606">Men</span>
###xml 350 353 <span type="species:ncbi:9606">men</span>
###xml 519 531 <span type="species:ncbi:9606">participants</span>
###xml 655 667 <span type="species:ncbi:9606">participants</span>
The Finnish cohort comprised 4457 male participants, aged from 50 to 70 years. Among them, 43.4% had a family history of diabetes. The primary aim of the ongoing METSIM (METabolic Syndrome In Men) trial is to investigate the effects of SNPs in genes of interest on the risk of type 2 diabetes and cardiovascular disease in a random sample of Finnish men, living in the town of Kuopio (population 95,000), in eastern Finland [4]. The WHO criteria in 1999 for diabetes mellitus were used for classification of the METSIM participants, based on fasting plasma glucose and 2-hour post-load glucose levels in an OGTT [28] conducted at baseline. Among the 4457 participants, 659 had known or newly diagnosed diabetes and 3798 were non-diabetic. The protocol includes a 1-day visit to the Clinical Research Unit of the University of Kuopio. This study was approved by the Ethics Committee of the University of Kuopio and was in accordance with the Helsinki Declaration.
###end p 27
###begin title 28
Body composition and body fat distribution
###end title 28
###begin p 29
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Body mass index (BMI) was calculated as weight divided by the square of height (kg/m2). Waist and hip circumferences were measured in the upright position.
###end p 29
###begin title 30
Analytical procedures
###end title 30
###begin p 31
Blood glucose was determined using a bedside glucose analyzer (Yellow Springs Instruments, Yellow Springs, CO, USA). Plasma insulin was determined by microparticle enzyme immunoassay (Abbott Laboratories, Tokyo, Japan) for both the TUEF and EUGENE2 cohorts. Plasma C-peptide was determined by radioimmunoassay (Byk-Sangtec, Dietzen bach, Germany).
###end p 31
###begin title 32
Oral glucose tolerance test (OGTT)
###end title 32
###begin p 33
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Alberti1">[28]</xref>
The OGTT was performed according to the recommendations of the World Health Organization after a 12 h fasting period [28]. Blood glucose, insulin (all centres), and C-peptide (TUEF cohort only) plasma levels were determined at 0, 30, 60, 90, and 120 min.
###end p 33
###begin title 34
Insulin sensitivity and insulin secretion
###end title 34
###begin p 35
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Matsuda1">[29]</xref>
###xml 380 382 380 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CP</sub>
###xml 412 415 412 415 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ins</sub>
###xml 493 496 493 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 560 564 560 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Utzschneider1">[30]</xref>
Insulin sensitivity was calculated from glucose and insulin values obtained during the OGTT, as proposed by Matsuda and DeFronzo [29]. Estimation of insulin secretion by the OGTT parameters was obtained by C-peptide levels measured at 30 min during the OGTT. Alternatively, insulin secretory function was calculated by the ratio of the area under the curve (AUC) of C-peptide (AUCCP; TUEF cohort) or insulin (AUCIns; EUGENE2 cohort) plasma levels, referred to as the AUC of plasma glucose (AUCGlc), using the trapezoidal approximation rule for AUC calculation [30].
###end p 35
###begin title 36
SNP Genotyping
###end title 36
###begin p 37
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 288 289 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 319 322 319 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
The SGK (NM_005627) gene on chromosome 6q23 was subjected to Hap Map analysis in the CEU population (Utah residents with ancestry from Northern and Western Europe; data release 21a/Jan07). Tagging SNPs were selected using the TagSNP Picker software (settings: multimarker mode MAF>0.05, r2>0.9), screening the complete SGK gene, 10 kb of the promoter, and 1.5 kb downstream of the 3' untranslated region. Genotyping of tagging SNPs was accomplished by means of the TaqMan(R) assay and an ABI Prism 7500 sequence detection system (Applied Biosystems, Foster City, CA, USA). Genotyping quality was tested by including three known controls of each genotype in each assay.
###end p 37
###begin title 38
Data Analysis
###end title 38
###begin p 39
###xml 197 198 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 551 552 547 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 561 562 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 902 906 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Carter1">[31]</xref>
Unless otherwise noted, data are stated as means+/-SEM. Comparison between genotype groups was performed using logarithmically transformed data for non-normally distributed parameters in ANOVA and t-tests. Each effect was adjusted for relevant covariates using mixed linear models. Parameters that remained non-normally distributed despite log transformation were directly analyzed by a non-parametric (Wilcoxon) test. Association with diabetes (METSIM) was tested using logistic regression analysis. Hardy-Weinberg equilibrium was tested with the chi2 test. A p-value</=0.05 was considered to be statistically significant. The software package JMP (SAS Institute Inc, Cary, NC, USA) and SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA) were used for statistical data analysis. The software JLIN (Western Australian Institute for Medical Research) was used for calculation of linkage disequilibrium [31].
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 24 29 <span type="species:ncbi:9606">human</span>
Genetic analysis of the human SGK gene
###end title 41
###begin p 42
###xml 10 13 10 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 100 103 100 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 504 507 504 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 582 585 582 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 621 624 621 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 743 750 743 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003506-g001">Fig. 1A</xref>
###xml 806 813 806 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003506-g001">Fig. 1B</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human SGK gene comprises 12 exons spanning 5.6 kb on chr6q23. Analysis of a 17 kb region of the SGK locus by Tag SNP Picker revealed five tagSNPs in the HapMap, each with a minor allele frequency (MAF) of >0.05 in the CEU population. Four SNPs (rs1763527, rs1743966, rs1057293, and rs9402571) were finally selected for genotyping, covering 83% of all SNPs fulfilling the inclusion criteria mentioned above. Both rs1743966 (intron 6) and rs1057293 (exon 8; synonymous: Asp/Asp) are located within the SGK gene, while rs1763527 (promoter) and rs9402571 (1429 bp downstream of the SGK 3'UTR) tag the regions surrounding SGK. MAF and Hardy-Weinberg-Equilibrium test results of all tagging SNPs are indicated for the TUEF and EUGENE2 cohort in Fig. 1A, with linkage disequilibrium (LD) analysis provided in Fig. 1B.
###end p 42
###begin title 43
###xml 18 23 <span type="species:ncbi:9606">human</span>
The gene encoding human serum- and glucocorticoid-regulated kinase 1 (SGK) on chromosome 6q23.
###end title 43
###begin p 44
###xml 382 383 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 619 620 615 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
A) Exons (light grey) and untranslated regions (dark grey) are indicated. Four tagging SNPs were selected by HapMap analysis considering the SGK gene +/-10 kb upstream of the first translational start codon and 1.5 kb downstream of the 3' untranslated region. SNP information is provided in boxes (var = variation; MAF = minor allele frequency; HWE = Hardy-Weinberg equilibrium, chi2 test) for populations investigated for all tagging SNPs (South German TUEF cohort/Finnish METSIM cohort). B) Linkage disequilibrium analysis of selected tagging SNPs for the TUEF and METSIM population: D' (in bold, upper numeral) and r2 (bottom numeral).
###end p 44
###begin title 45
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
SGK association analyses in the TUEF screening cohort
###end title 45
###begin p 46
###xml 302 309 302 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003506-t002">Table 2</xref>
###xml 593 602 593 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C-Peptide</sub>
###xml 606 609 606 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 685 692 685 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003506-t002">Table 2</xref>
There was no association between genotypes, anthropometrics, and insulin sensitivity in the south German screening cohort, which was investigated for all four tagging SNPs (data not shown). Most consistently, two different indices of insulin secretion differed significantly among rs9402571 genotypes (Table 2). Minor allele carriers of rs9402571 had significantly higher C-Peptide levels in the 2 h OGTT than individuals with the wild type allele (+10.8%, p = 0.04, dominant model), after adjustment for age, gender, BMI, and insulin sensitivity. This genotype also associated with better AUCC-Peptide/AUCGlc ratios (+7.5%, p = 0.04; dominant model, adjusted for age, BMI and gender; Table 2).
###end p 46
###begin title 47
Metabolic Traits of the German Cohort according to rs9402571 genotype.
###end title 47
###begin p 48
###xml 32 33 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 51 52 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Data are given as means+/-SEM; p1-additive model; p2-dominant model. AUC-area under the curve; OGTT-oral glucose tolerance test; SNP-single nucleotide polymorphism.
###end p 48
###begin p 49
adjusted for age and gender.
###end p 49
###begin p 50
adjusted for age, gender and BMI.
###end p 50
###begin p 51
adjusted for age, gender, BMI and insulin sensitivity.
###end p 51
###begin title 52
Interaction analysis and replication in EUGENE2
###end title 52
###begin p 53
###xml 395 396 395 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 614 616 614 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CP</sub>
###xml 620 623 620 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 682 684 680 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</italic>
###xml 695 697 691 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TG</italic>
###xml 708 710 702 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GG</italic>
###xml 722 723 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 800 807 792 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003506-g002">Fig. 2A</xref>
###xml 1128 1131 1120 1123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ins</sub>
###xml 1135 1138 1127 1130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 1189 1192 1181 1184 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ins</sub>
###xml 1196 1199 1188 1191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 1226 1228 1218 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</italic>
###xml 1239 1241 1229 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TG</italic>
###xml 1252 1254 1240 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GG</italic>
###xml 1266 1267 1252 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1389 1396 1375 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003506-g002">Fig. 2B</xref>
###xml 902 914 <span type="species:ncbi:9606">participants</span>
An interaction analysis for the trait of insulin secretion was performed. BMIxrs9402571 genotype was revealed to be significantly relevant for the endpoint insulin secretion in TUEF, independent of which calculation model for insulin secretion was used (p = 0.04, both models) and of whether BMI was treated as a continuous or discrete variable with BMI cut-off points ranging from 24 to 28 kg/m2. We therefore stratified the cohort for BMI, using a cut off point of BMI = 25 to distinguish lean from overweight or obese individuals, and did a reanalysis for insulin secretion for both subgroups. The effect on AUCCP/AUCGlc was only significant in the lean TUEF subgroup (BMI</=25: TT: 318+/-5, TG: 335+/-7, GG: 342+/-17; p = 0.031; dominant model, adjusted for age, gender, and insulin sensitivity; Fig. 2A), while there was no association with insulin secretory function in overweight to obese study participants (BMI>25; p>0.24, all; additive and dominant models; data not shown). To replicate our findings of the association between rs9402571 and insulin secretion, the EUGENE2 cohort was genotyped for rs9402571 and the AUCIns/AUCGlc ratio was calculated for each genotype. Again, AUCIns/AUCGlc was significantly higher (TT: 226+/-7, TG: 239+/-9, GG: 289+/-33; p  = 0.019 for the dominant model; adjusted for study centre, familial relationship, age, gender, and insulin sensitivity; Fig. 2B) in lean (BMI</=25) minor allele carriers of rs9402571, while there was no significant association in overweight to obese individuals (BMI>25: p>0.44; data not shown).
###end p 53
###begin title 54
Insulin secretion of the TUEF and EuGene2 Cohort, according to rs9402571 genotype in lean subjects (BMI<25).
###end title 54
###begin p 55
###xml 84 86 84 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CP</sub>
###xml 107 110 107 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 236 239 236 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ins</sub>
###xml 260 263 260 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Glc</sub>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
A) TUEF cohort: The ratio of the area under the curve (AUC) of C-Peptide values (AUCCP) to AUC glucose (AUCGlc) in the OGTT was adjusted for age, gender and insulin sensitivity (Matsuda). B) EUGENE2 cohort: the ratio of AUC insulin (AUCIns) to AUC glucose (AUCGlc) was adjusted for centre, familial relationship, age, gender and insulin sensitivity. Only individuals with a BMI<25 kg/m2 were included for both analysis. Data are presented as means+/-SEM. p-values are shown for both the additive and dominant model.
###end p 55
###begin title 56
Diabetes risk analysis in the METSIM population-based cohort
###end title 56
###begin p 57
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 695 698 695 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 749 755 749 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003506-g003">Fig. 3</xref>
###xml 540 548 <span type="species:ncbi:9606">patients</span>
###xml 583 595 <span type="species:ncbi:9606">participants</span>
The METSIM cohort was genotyped for all four selected tagging SNPs to analyze SGK genetic variance for the endpoint diabetes (type 2) in a population-based cohort. The minor allele of rs9402571, which was found to associate with a higher insulin secretion in the screening (TUEF) as well as the replication (EUGENE2) populations, associated almost significantly (p = 0.065; adjusted for age, family history of diabetes, and BMI) with a lower prevalence of type 2 diabetes (odds ratio: 0.845; 95%CI: 0.706-1.011), comparing the 659 diabetic patients with the non-diabetic 3798 METSIM participants. In contrast, there was no significantly altered odds ratio in regard to the three other genotyped SGK tagging SNPs rs1763527, rs1743966, and rs1057293 (Fig. 3).
###end p 57
###begin title 58
Diabetes risk (METSIM study) according to SGK genetic variability.
###end title 58
###begin p 59
The odds ratio, 95% confidence intervals (CI) and forest plot for the endpoint "type 2 diabetes" are presented for the minor alleles of each SGK tagging SNP. N = 658 diabetic and N = 3746 non-diabetic subjects of the Finish METSIM study cohort were investigated. The p-values were calculated for a dominant model. SNP = single nucleotide polymorphism.
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 338 341 338 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Lang1">[16]</xref>
###xml 543 547 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Ullrich1">[22]</xref>
###xml 549 553 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Ullrich2">[23]</xref>
###xml 412 418 <span type="species:ncbi:9606">humans</span>
This is the first study to investigate the role of SGK (Serum- and Glucocorticoid-inducible Kinase 1) genetic variance in two independent prediabetic diabetes risk populations (TUEF and EUGENE2), including a confirmatory analysis in a third independent, older population that includes both diabetic and non-diabetic individuals (METSIM). SGK is an attractive candidate gene for type 2 diabetes mellitus onset in humans, as SGK1 exerts pleiotropic effects on glucose metabolism and insulin secretion in various cellular and animal models [16], [22], [23].
###end p 61
###begin p 62
###xml 1096 1100 1096 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Dieter1">[18]</xref>
###xml 1102 1106 1102 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Palmada1">[20]</xref>
###xml 1108 1112 1108 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Jeyaraj1">[21]</xref>
###xml 1154 1157 1154 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 1291 1294 1291 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 1545 1548 1545 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 1634 1638 1634 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003506-Atwood1">[32]</xref>
###xml 1591 1603 <span type="species:ncbi:9606">participants</span>
In the screening population (TUEF; N = 725), we found a significant association of rs9402571 with glucose-induced insulin secretion in various estimation models based on oral glucose tolerance testing. This association was reproducible in a subgroup that was additionally phenotyped by an intravenous glucose tolerance test (data not shown). After confirming a significant interaction between BMI and rs9402571 for the endpoint insulin secretion, BMI stratification (BMI cut off: 25) was introduced in our analysis, revealing that only lean individuals were affected by the rs9402571 minor allele. This genotype-phenotype association was also restricted to lean individuals in the replication cohort from the EUGENE2 consortium (N = 827), comprising individuals from Sweden, Italy, Denmark, Finland, and Germany. Interestingly, the rs9402571 allele that associates with higher insulin secretion in TUEF and EUGENE2 accordingly associates with lower diabetes prevalence in the METSIM trial. Despite the fact that SGK1 has a regulatory function for glucose transporter expression and translocation [18], [20], [21], no association of the four investigated SGK tagging SNPs with insulin sensitivity was found in the TUEF screening population or in the EUGENE2 study. One could suggest that the SGK rs9402571 SNP was not detected in the genome-wide association (GWA) studies due to its dependence on BMI, as the GWA analyses did not stratify for BMI. Interestingly, a genome-wide linkage analysis identified the gene locus 6q23, which also includes SGK, to be associated with BMI progression in participants of the Framingham Heart Study [32].
###end p 62
###begin p 63
###xml 258 261 258 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 380 383 380 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 474 477 474 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 832 835 832 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGK</italic>
###xml 671 683 <span type="species:ncbi:9606">participants</span>
###xml 933 938 <span type="species:ncbi:9606">human</span>
The increase in insulin secretion reported here (10.8% in TUEF; 8.8% in EUGENE2) within lean rs9402571 G allele carriers was remarkable compared to wild type genotype, and may indicate a protective genotype against type 2 diabetes. This protective rs9402571 SGK genotype may become blurred in overweight or obese individuals, as environmental factors may dominate compared to the SGK genotype. However, our analysis in the METSIM trial assumed that the protective rs9402571 SGK genotype effect obviously persists even in a population-based cohort containing individuals 20 years older than those from the TUEF and EUGENE2 studies. Therefore, although the number of study participants was limited after BMI stratification in both TUEF and EUGENE2, our findings in three independent European populations allow the assumption that the SGK rs9402571 genotype is protective against type 2 diabetes. Further studies on the role of SGK1 in human insulin secretion and diabetes onset are therefore needed.
###end p 63
###begin p 64
The authors acknowledge the excellent technical assistance of Melanie Weisser, Alke Guirguis, Roman Werner, Heike Luz, and Anna Bury.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.
###end article-title 66
###begin article-title 67
###xml 75 80 <span type="species:ncbi:9606">human</span>
Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets.
###end article-title 67
###begin article-title 68
Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.
###end article-title 68
###begin article-title 69
Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion.
###end article-title 69
###begin article-title 70
Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the Insulin Resistance Atherosclerosis Family Study.
###end article-title 70
###begin article-title 71
Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function.
###end article-title 71
###begin article-title 72
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes.
###end article-title 72
###begin article-title 73
###xml 175 178 <span type="species:ncbi:9606">men</span>
Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance.
###end article-title 73
###begin article-title 74
Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function.
###end article-title 74
###begin article-title 75
###xml 141 149 <span type="species:ncbi:9606">patients</span>
The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients-the EUGENE2 study.
###end article-title 75
###begin article-title 76
Gene-environment interactions in the pathogenesis of type 2 diabetes and metabolism.
###end article-title 76
###begin article-title 77
A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study.
###end article-title 77
###begin article-title 78
Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies.
###end article-title 78
###begin article-title 79
Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum.
###end article-title 79
###begin article-title 80
Epithelial sodium channel regulated by aldosterone-induced protein sgk.
###end article-title 80
###begin article-title 81
(Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms.
###end article-title 81
###begin article-title 82
Serum- and glucocorticoid-inducible kinase 1 mediates salt sensitivity of glucose tolerance.
###end article-title 82
###begin article-title 83
Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB.
###end article-title 83
###begin article-title 84
###xml 37 41 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Intestinal function of gene-targeted mice lacking serum- and glucocorticoid-inducible kinase 1.
###end article-title 84
###begin article-title 85
SGK1 kinase upregulates GLUT1 activity and plasma membrane expression.
###end article-title 85
###begin article-title 86
Role of SGK1 kinase in regulating glucose transport via glucose transporter GLUT4.
###end article-title 86
###begin article-title 87
Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion.
###end article-title 87
###begin article-title 88
Dexamethasone increases Na+/K+ ATPase activity in insulin secreting cells through SGK1.
###end article-title 88
###begin article-title 89
Serum- and glucocorticoid-regulated kinase (SGK1) gene and blood pressure.
###end article-title 89
###begin article-title 90
Genetic variance of SGK-1 is associated with blood pressure, blood pressure change over time and strength of the insulin-diastolic blood pressure relationship.
###end article-title 90
###begin article-title 91
###xml 134 142 <span type="species:ncbi:9606">patients</span>
Reduced skeletal muscle oxygen uptake and reduced beta-cell function: two early abnormalities in normal glucose-tolerant offspring of patients with type 2 diabetes.
###end article-title 91
###begin article-title 92
###xml 75 82 <span type="species:ncbi:9606">persons</span>
Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.
###end article-title 92
###begin article-title 93
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
###end article-title 93
###begin article-title 94
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.
###end article-title 94
###begin article-title 95
Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies.
###end article-title 95
###begin article-title 96
JLIN: a java based linkage disequilibrium plotter.
###end article-title 96
###begin article-title 97
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study.
###end article-title 97
###begin p 98
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 98
###begin p 99
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The study was supported by grants from the Deutsche Forschungsgemeinschaft (KFO 114, Heisenberg-Grant to NS: STE 1096/1-1), the European Community's FP6 EUGENE2 (LSHM-CT-2004-512013) and by an intramural grant from the Medical Faculty of the University of Tubingen (Fortune Program Nr. 1212-0-0 to BF).
###end p 99

